Delta 508 mutation at Dr. Essa Lab

Delta 508 mutation at Dr. Essa Lab

The Delta 508 mutation test, clinically designated as the F508del mutation analysis, is a highly specialized molecular genetic test designed to detect the most common genetic alteration associated with Cystic Fibrosis (CF). This mutation occurs within the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene located on the long arm of chromosome 7. At Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, this advanced molecular assay is performed using state-of-the-art Polymerase Chain Reaction (PCR) and hybridization technologies. The test plays a critical role in identifying individuals who carry the mutation, diagnosing patients with clinical symptoms of cystic fibrosis, and assisting couples with preconception genetic planning.

The CFTR gene is responsible for encoding a specialized protein channel that regulates the transport of chloride ions and water across cellular membranes in epithelial tissues. This regulation is vital for maintaining the fluidity of mucus, sweat, saliva, tears, and digestive enzymes. The Delta 508 mutation involves a specific three-base pair deletion (cytosine-thymine-thymine) at codon 508 of the CFTR gene, resulting in the loss of a single amino acid, phenylalanine. Without this phenylalanine residue, the CFTR protein cannot fold into its correct three-dimensional structure. Consequently, the cellular quality control machinery recognizes the protein as defective and degrades it within the endoplasmic reticulum before it can reach the cell membrane. This complete or near-complete absence of functional chloride channels leads to the production of abnormally thick, sticky mucus in multiple organ systems, most notably the lungs, pancreas, liver, and reproductive tract.

By utilizing advanced molecular diagnostic platforms, Dr. Essa Lab provides highly accurate detection of this mutation. This test is of paramount clinical importance because the F508del mutation accounts for approximately 70% of cystic fibrosis alleles worldwide. Identifying this mutation early allows for prompt clinical intervention, personalized treatment strategies, and informed reproductive decisions. The diagnostic value of this test extends from newborn screening confirmation to adult carrier detection, offering a definitive genetic answer that guides lifelong medical management.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of accuracy and a smooth testing experience at Dr. Essa Lab, patients should observe the following preparation guidelines:

• No Fasting Required: Unlike routine biochemistry tests, the Delta 508 mutation test does not require fasting. Patients may eat and drink normally before the sample collection.
• Medication Disclosure: Patients must inform the laboratory staff and their physician of all ongoing medications, especially recent blood transfusions or immunosuppressive therapies, which can occasionally interfere with molecular testing.
• Genetic Counseling: It is highly recommended that patients undergo pre-test genetic counseling to fully understand the clinical, psychological, and familial implications of genetic testing.
• Informed Consent: Since this is a genetic test, patients or their legal guardians will be required to sign an informed consent form prior to sample collection.
• Identification Documents: Please bring valid identification and the physician’s referral slip to ensure accurate patient registration and tracking.

During the Procedure

The molecular testing process at Dr. Essa Lab is designed to be safe, efficient, and minimally invasive. The procedure involves the following steps:

• Sanitization and Safety: The phlebotomist will clean the venipuncture site (usually the inner elbow) with an antiseptic solution to prevent contamination.
• Sample Collection: A small volume of peripheral blood (typically 3 to 5 mL) is drawn from a vein using a sterile, single-use needle. The blood is collected directly into an EDTA (purple-top) tube, which prevents clotting and preserves the integrity of the cellular DNA.
• Alternative Sampling: In specific pediatric or clinical cases where venipuncture is difficult, a buccal (cheek) swab may be utilized to collect epithelial cells for DNA extraction, as directed by the clinical pathologist.
• Labeling and Transport: The sample tube is immediately labeled with unique patient identifiers and barcodes to prevent pre-analytical errors. It is then transported under temperature-controlled conditions to the molecular biology department.
• Duration: The physical collection process takes less than five minutes. The patient may experience a mild, brief pinching sensation during needle insertion.
• Post-Collection Care: Gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a small bandage. Patients can resume their daily activities immediately after the procedure.

When is a Delta 508 mutation Test Performed?

Diagnosis of Cystic Fibrosis in Symptomatic Infants

Physicians request the Delta 508 mutation test when an infant or young child exhibits classic clinical symptoms of cystic fibrosis. These symptoms include persistent, unexplained respiratory infections, chronic coughing, wheezing, failure to thrive despite a vigorous appetite, and abnormally salty-tasting skin. The test assists the pediatrician by confirming whether these systemic manifestations are rooted in the homozygous F508del genetic defect, allowing for the immediate initiation of specialized pulmonary and nutritional therapies.

Carrier Screening for Prospective Parents

For couples planning a pregnancy, particularly those with a known family history of cystic fibrosis or chronic respiratory disorders, carrier screening is vital. Because cystic fibrosis is inherited in an autosomal recessive pattern, a child must inherit one mutated gene from each parent to develop the disease. If both parents are identified as carriers of the Delta 508 mutation, they have a 25% chance of passing the disease to their offspring with each pregnancy. This test provides essential genetic risk assessment and enables couples to explore prenatal diagnosis or assisted reproductive technologies.

Newborn Screening Follow-up

Many modern neonatal healthcare protocols include screening for cystic fibrosis by measuring immunoreactive trypsinogen (IRT) levels in a newborn’s blood spot. If the IRT level is elevated, it indicates potential pancreatic injury or cystic fibrosis. To confirm or rule out the diagnosis, clinicians order the Delta 508 mutation test as a definitive second-tier molecular assay. This rapid genetic confirmation ensures that affected infants receive specialized care before severe nutritional deficiencies or lung damage occur.

Evaluation of Male Infertility

A significant percentage of men presenting with obstructive azoospermia (the absence of sperm in semen due to physical blockage) are found to have Congenital Bilateral Absence of the Vas Deferens (CBAVD). This condition is highly associated with mutations in the CFTR gene, even in the absence of pulmonary or digestive symptoms of cystic fibrosis. Urologists and reproductive endocrinologists order the Delta 508 mutation test to determine if a genetic defect is the underlying cause of infertility, which is crucial before proceeding with assisted reproductive techniques like Intracytoplasmic Sperm Injection (ICSI).

Atypical Cystic Fibrosis Symptoms in Adults

In some cases, individuals with milder or atypical mutations on one allele paired with the Delta 508 mutation on the other may not be diagnosed until adulthood. These patients often present with recurrent episodes of acute pancreatitis, chronic rhinosinusitis, nasal polyps, or progressive bronchiectasis. Pulmonologists and gastroenterologists utilize this genetic test to establish a late-stage diagnosis of atypical cystic fibrosis, which helps tailor targeted therapies to prevent further organ damage.

What Does a Delta 508 mutation Test Detect?

The molecular analysis of the CFTR gene at Dr. Essa Lab is highly precise and can detect several genetic states and clinical correlations, including:

• Homozygous F508del Mutation: Detects the presence of two copies of the Delta 508 mutation (one inherited from each parent), confirming a diagnosis of classic cystic fibrosis.
• Heterozygous F508del Mutation: Detects a single copy of the Delta 508 mutation, identifying the individual as a healthy carrier of cystic fibrosis.
• Wild-Type Alleles: Confirms the absence of the Delta 508 mutation on both chromosomes, indicating a normal genetic sequence at codon 508.
• Risk of Severe Pancreatic Insufficiency: Homozygosity for F508del is strongly correlated with pancreatic exocrine insufficiency, requiring lifelong pancreatic enzyme replacement therapy.
• Predisposition to Meconium Ileus: Identifies newborns at high risk for meconium ileus, a severe bowel obstruction occurring shortly after birth.
• Susceptibility to Chronic Bronchiectasis: Detects the genetic basis for permanent dilation of the airways, leading to mucus retention and recurrent infections.
• Risk of Pseudomonas aeruginosa Colonization: Correlates with an increased likelihood of early and persistent airway colonization by opportunistic bacterial pathogens.
• Congenital Bilateral Absence of the Vas Deferens (CBAVD): Identifies the genetic etiology of obstructive azoospermia in infertile males.
• Correlation with High Sweat Chloride Levels: Homozygous findings align with sweat chloride diagnostic thresholds exceeding 60 mmol/L.
• Risk of Cystic Fibrosis-Related Diabetes (CFRD): Detects the genetic background associated with progressive endocrine pancreatic damage and insulin deficiency.
• Predisposition to Distal Intestinal Obstruction Syndrome (DIOS): Identifies patients prone to partial or complete fecal obstructions in the ileocecal region.
• Risk of CF-Associated Liver Disease (CFALD): Correlates with potential focal biliary cirrhosis, portal hypertension, and gallbladder disease.
• Fat-Soluble Vitamin Deficiencies: Highlights the risk of malabsorption of vitamins A, D, E, and K due to pancreatic duct obstruction.
• Potential for Metabolic Alkalosis: Identifies infants at risk for chronic salt wasting, dehydration, and hypokalemic alkalosis during hot weather.
• Eligibility for CFTR Modulator Therapies: Determines if a patient is a candidate for highly effective modulator drugs (such as Lumacaftor/Ivacaftor or Tezacaftor/Ivacaftor) designed specifically for the F508del protein folding defect.
• Familial Genetic Risk Patterns: Provides critical data to map out inheritance risks for siblings, offspring, and extended family members.
• Indication for Prenatal Testing: Guides the necessity of amniocentesis or chorionic villus sampling (CVS) in future pregnancies.
• Correlation with Low Fecal Elastase: Aligns with clinical findings of severe exocrine pancreatic dysfunction.
• Atypical CF Phenotypes: Helps identify compound heterozygotes when combined with broader CFTR gene sequencing panels.
• Prognostic Pulmonary Decline Rate: Assists pulmonologists in predicting the potential trajectory of forced expiratory volume (FEV1) decline over time.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing accurate and timely molecular diagnostic reports. Because genetic testing involves complex DNA extraction, amplification, and hybridization phases, the turnaround time for the Delta 508 mutation test is typically within 7 to 10 working days. This timeline ensures that multiple quality control checks are completed, and the results are verified by a consultant molecular pathologist.

Patients and referring physicians can access reports conveniently through the Dr. Essa Lab online portal. Once the report is finalized, an automated SMS notification is sent to the patient’s registered mobile number with a direct link to download the secure PDF report. Physical copies can also be collected from any of the numerous Dr. Essa Lab diagnostic centers across Karachi and other major cities. The reports are presented in a clear, structured format, detailing the genetic methodology used, the specific alleles detected, and a comprehensive clinical interpretation of the findings.

Delta 508 mutation Findings Overview

The following table outlines the genetic parameters evaluated during the Delta 508 mutation analysis, along with their normal and abnormal clinical implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CFTR Gene Codon 508 Status	No mutation detected (Wild-type sequence)	Deletion of three base pairs (CTT) at codon 508 (F508del)
Zygosity / Carrier Status	Non-carrier (Two normal alleles)	Heterozygous (one mutated allele) or Homozygous (two mutated alleles)
Clinical Phenotype	Normal respiratory and digestive function	Classic Cystic Fibrosis (homozygous) or asymptomatic carrier (heterozygous)
Pancreatic Exocrine Function	Normal secretion of digestive enzymes	Severe pancreatic insufficiency, malabsorption, steatorrhea (homozygous)
Pulmonary Mucociliary Clearance	Normal, thin mucus transport in airways	Thick, dehydrated mucus, chronic bronchiectasis, recurrent pneumonia
Male Reproductive Tract Development	Normal development of the vas deferens	Congenital Bilateral Absence of the Vas Deferens (CBAVD) leading to infertility
Sweat Gland Chloride Secretion	Normal sweat chloride levels (<30 mmol/L)	Elevated sweat chloride levels (>60 mmol/L in homozygous individuals)
CFTR Protein Expression	Fully functional protein channels at the cell membrane	Misfolded protein degraded in the endoplasmic reticulum (no membrane expression)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Delta 508 mutation?

• Experienced Healthcare Professionals: Our molecular biology department is staffed by highly trained geneticists, pathologists, and technologists specializing in hereditary disorders.
• Patient-Focused Care: We prioritize patient comfort, confidentiality, and clear communication throughout the genetic testing process.
• Quality Diagnostic Services: Dr. Essa Lab adheres to strict international quality control standards, ensuring maximum accuracy and reproducibility of genetic results.
• Professional Reporting: Reports are detailed, clinically structured, and signed by certified consultant pathologists to assist clinicians in precise decision-making.
• Modern Diagnostic Approach: We utilize advanced PCR and molecular hybridization platforms to detect genetic mutations with high sensitivity and specificity.
• Comfortable Environment: Our diagnostic centers are designed to provide a welcoming, hygienic, and stress-free environment for patients of all ages.
• Convenient Location: With an extensive network of collection points across Karachi and Pakistan, accessing specialized molecular testing is highly convenient.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built decades of trust through its unwavering commitment to diagnostic excellence and ethical medical practices.